Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03850548 |
|
Recruitment Status :
Completed
First Posted : February 22, 2019
Last Update Posted : February 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Bone and Joint Infection | Other: Prosthetic joint infection with Cutibacterium acnes |
| Study Type : | Observational |
| Actual Enrollment : | 6 participants |
| Observational Model: | Cohort |
| Time Perspective: | Retrospective |
| Official Title: | Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR : Descriptive Study of 6 Patients |
| Actual Study Start Date : | January 1, 2016 |
| Actual Primary Completion Date : | March 1, 2017 |
| Actual Study Completion Date : | February 1, 2018 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Prosthetic joint infection with Cutibacterium acnes
Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
|
Other: Prosthetic joint infection with Cutibacterium acnes
patients having a prosthesis infection with C.acnes identified by specific PCR |
- Rate of diagnostic delay [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]time between surgery and detection of C. acnes by PCR
- rate of radiologic signs [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]prosthesis loosening or not
- rate of duration of antibiotherapy [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]measures of duration of the antibiotherapy
- rate of use of this diagnostic [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]descriptions of patients managed with this diagnostic
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients having had infection prothesis vith C. acnes identified by PCR
Exclusion Criteria:
- none
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03850548
| France | |
| Hospices Civils de Lyon | |
| Lyon, France, 69004 | |
| Study Director: | Tristan Ferry, Md,PhD | HCL |
| Responsible Party: | Eugénie MABRUT, clinical research assistant, Hospices Civils de Lyon |
| ClinicalTrials.gov Identifier: | NCT03850548 |
| Other Study ID Numbers: |
18-031 |
| First Posted: | February 22, 2019 Key Record Dates |
| Last Update Posted: | February 22, 2019 |
| Last Verified: | February 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
bone and joint infection Propionibacterium acnes Cutibacterium acnes |
|
Infections Communicable Diseases Disease Attributes Pathologic Processes |

